Biologic drugs for the treatment of hidradenitis suppurativa: An evidence-based review

Dermatologic Clinics

Volumn 28, Issue 3, 2010, Pages 511-524

  Shuja, Fareesa ^a   Chan, C Stanley ^a   Rosen, Ted ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Abscesses; Biologics; Hidradenitis suppurativa; Nodules

Indexed keywords

ADALIMUMAB; ALEFACEPT; AZATHIOPRINE; AZTREONAM; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; ISOTRETINOIN; LEVOFLOXACIN; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; PLACEBO; RETINOID; SALAZOSULFAPYRIDINE; STEROID; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALLERGIC REACTION; ANAPHYLACTIC SHOCK; ANKYLOSING SPONDYLITIS; APLASTIC ANEMIA; ARTHRALGIA; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; BLOOD PRESSURE; BRONCHOSPASM; CANCER PAIN; CANDIDIASIS; CARPAL TUNNEL SYNDROME; CHEST TIGHTNESS; CHORIORETINITIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSERVATIVE TREATMENT; CROHN DISEASE; DEMYELINATING DISEASE; DISCOID LUPUS ERYTHEMATOSUS; DISEASE SEVERITY; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EVIDENCE BASED MEDICINE; FATIGUE; FLU LIKE SYNDROME; HEART MUSCLE CONDUCTION DISTURBANCE; HEPATITIS B; HERPES ZOSTER; HOT FLUSH; HUMAN; HYPERSENSITIVITY REACTION; INJECTION SITE INFECTION; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LIVER TOXICITY; LOW DRUG DOSE; LUPUS LIKE SYNDROME; LUPUS VULGARIS; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; MOTOR NEUROPATHY; MYALGIA; NAUSEA; NECROTIZING ARTERITIS; PANCYTOPENIA; PARESTHESIA; POSTPRIMARY TUBERCULOSIS; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SEPTICEMIA; SIDE EFFECT; SKIN INFECTION; SUPPURATIVE HIDRADENITIS; SWEATING; TEMPERATURE; TRADITIONAL MEDICINE; TREATMENT DURATION; ULCERATIVE COLITIS; URTICARIA; VIRUS REACTIVATION;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DERMATOLOGIC AGENTS; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; THERAPIES, INVESTIGATIONAL; YOUNG ADULT;

EID: 77953259764     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2010.03.012     Document Type: Review

References (50)

1. Brown T.J., Rosen T., Orengo I.F. Hidradenitis suppurativa. South Med J 1998, 91:1107-1114.
2. Wiseman M.C. Hidradenitis suppurativa: a review. Dermatol Ther 2004, 17:50-54.
3. Krbec A.C. Current understanding and management of hidradenitis suppurativa. J Am Acad Nurse Pract 2007, 19:228-234.
4. Ather S., Chan D.S., Leaper D.J., et al. Surgical treatment of hidradenitis suppurativa: case series and review of the literature. Int Wound J 2006, 3:159-169.
5. Sellheyer K., Krahl D. " Hidradenitis suppurativa" is acne inversa! An appeal to (finally) abandon a misnomer. Int J Dermatol 2005, 44:535-540.
6. Buimer M.G., Wobbes T., Klinkenbijl J.H. Hidradenitis suppurativa. Br J Surg 2009, 96:350-360.
7. Fitzsimmons J.S., Guilbert P.R. A family study of hidradenitis suppurativa. J Med Genet 1985, 22:367-373.
8. Shah N. Hidradenitis suppurativa: a treatment challenge. Am Fam Physician 2005, 72:1547-1552.
9. Mitchell K.M., Beck D.E. Hidradenitis suppurativa. Surg Clin North Am 2002, 82:1187-1197.
10. Giamarellos-Bourboulis E.J., Pelekanou E., Antonopoulou A., et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 2008, 158:567-572.
11. Cusack C., Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 2006, 154:726-729.
12. Sotiriou E., Apalla Z., Vakirlis E., et al. Efficacy of adalimumab in recalcitrant hidradenitis suppurativa. Eur J Dermatol 2009, 19:180-181.
13. Harbour R., Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001, 323:334-336.
14. Doherty C.B., Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs 2008, 68:1361-1383.
15. Weller R., Hunter J., Savin J., et al. Psoriasis. Clinical dermatology 2008, 68-69. Blackwell Publishing, Malden(MA). 4th edition. R. Weller, J. Hunter, J. Savin (Eds.).
16. Trent J.T., Kerdel F.A. Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases. Dermatol Nurs 2005, 17:97-107.
17. Gupta A.K., Skinner A.R. A review of the use of infliximab to manage cutaneous dermatoses. J Cutan Med Surg 2004, 8:77-89.
18. Traczewski P., Rudnicka L. Adalimumab in dermatology. Br J Clin Pharmacol 2008, 66:618-625.
19. Sotiriou E., Apalla Z., Ioannidos D. Etanercept for the treatment of hidradenitis suppurativa. Acta Derm Venereol 2009, 89:82-83.
20. Pedraz J., Penas P.F., Garcia-Diez A. Pachyonychia congenita and hidradenitis suppurativa: no response to infliximab therapy. J Eur Acad Dermatol Venereol 2008, 22:1500-1501.
21. Sellheyer K., Krahl D. What causes acne inversa (or hidradenitis suppurativa)?-the debate continues. J Cutan Pathol 2008, 35:795-797.
22. Yamauchi P.S., Mau N. Hidradenitis suppurativa managed with adalimumab. J Drugs Dermatol 2009, 8:181-183.
23. Scheinfeld N. Treatment of coincident seronegative arthritis and hidradentis supprativa with adalimumab. J Am Acad Dermatol 2006, 55:163-164.
24. Moul D.K., Korman N.J. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol 2006, 142:1110-1112.
25. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
26. Strober B.E., Kim C., Siu K. Efalizumab for the treatment of refractory hidradenitis suppurativa. J Am Acad Dermatol 2007, 57:1090-1091.
27. Pugashetti R., Koo J. Efalizumab discontinuation: a practical strategy. J Dermatolog Treat 2009, 20:132-136.
28. Lee R.A., Dommasch E., Treat J., et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2009, 60:565-573.
29. Henderson R.L. Case reports: treatment of atypical hidradenitis suppurativa with the tumor necrosis factor receptor-Fc fusion protein etanercept. J Drugs Dermatol 2006, 5:1010-1011.
30. Zangrilli A., Esposito M., Mio G., et al. Long-term efficacy of etanercept in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2008, 22:1260-1262.
31. Arriola-Villalobos P., Diaz-Valle D., Alejandre-Alba N., et al. Bilateral Candida chorioretinitis following etanercept treatment for hidradenitis suppurativa. Eye 2008, 22:599-600.
32. Alexis A.F., Strober B.E. Off-label dermatologic uses of anti-TNF-α therapies. J Cutan Med Surg 2005, 9:296-302.
33. Adams D.R., Gordon K.B., Devenyi A.G., et al. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol 2003, 139:1540-1542.
34. Goertz R.S., Konturek P.C., Naegel A., et al. Experiences with a long-term treatment of a massive gluteal acne inversa with infliximab in Crohn's disease. Med Sci Monit 2009, 15:CS14-CS18.
35. Katsanos K.H., Christodoulou D.K., Tsianos E.V. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Am J Gastroenterol 2002, 97:2155-2156.
36. Lebwohl B., Sapadin A.N. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2003, 49:S275-S276.
37. Martinez F., Nos P., Benlloch S., et al. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 2001, 7:323-326.
38. Montes-Romero J.A., Callejas-Rubio J.L., Sanchez-Cano D., et al. Amyloidosis secondary to hidradenitis suppurativa. Exceptional response to infliximab. Eur J Intern Med 2008, 19:e32-e33.
39. Rosi Y.L., Lowe L., Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat 2005, 16:58-61.
40. Thielen A.M., Barde C., Saurat J.H. Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol 2006, 155:1105-1107.
41. Moschella S.L. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int J Dermatol 2007, 46:1287-1291.
42. Antonucci A., Negosanti M., Negosanti L., et al. Acne inversa treated with infliximab: different outcomes in 2 patients. Acta Derm Venereol 2008, 88:274-275.
43. Sullivan T.P., Welsh E., Kerdel F.A., et al. Infliximab for hidradenitis suppurativa. Br J Dermatol 2003, 149:1046-1049.
44. Fardet L., Dupuy A., Kerob D., et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 2007, 56:624-628.
45. Usmani N., Clayton T.H., Everett S., et al. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol 2007, 32:204-205.
46. Fernández-Vozmediano J.M., Armario-Hita J.C. Infliximab for the treatment of hidradenitis suppurativa. Dermatology 2007, 215:41-44.
47. Pedraz J., Dauden E., Perez-Gala S., et al. Actas Dermosifiliogr 2007, 98:325-331. [in Spanish].
48. Mekkes J.R., Bos J.D. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 2008, 158:370-374.
49. Brunasso A.M., Delfino C., Massone C. Hidradenitis suppurativa: are tumour necrosis factor-alpha blockers the ultimate alternative?. Br J Dermatol 2008, 159:761-763.
50. Lecluse L.L., Piskin G., Mekkes J.R., et al. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol 2008, 159:527-536.